Literature DB >> 911666

A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.

T J McElwain, J Toy, E Smith, M J Peckham, D E Austin.   

Abstract

Seventy patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP). The complete remission rate of 75-7% compares well with that produced by other combinations. The combination is non-toxic, easily administered and can be given safely to outpatients. Its main advantage is that it is far less upsetting to patients than combinations containing nitrogen mustard.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 911666      PMCID： PMC2025471          DOI： 10.1038/bjc.1977.187

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  5 in total

1.  COMBINED VINBLASTINE AND CHLORAMBUCIL THERAPY OF HODGKIN'S DISEASE.

Authors:  M J LACHER; J R DURANT
Journal:  Ann Intern Med       Date:  1965-03       Impact factor: 25.391

2.  Combination chemotherapy in advanced and recurrent Hodgkin's disease.

Authors:  T J McElwain; P F Wrigley; A Hunter; D Crowther; J S Malpas; M J Peckham; D W Smithers; G H Fairley
Journal:  Natl Cancer Inst Monogr       Date:  1973-05

3.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

4.  Combination chemotherapy in generalized Hodgkin's disease.

Authors:  W M Nicholson; M E Beard; D Crowther; A G Stansfeld; C P Vartan; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1970-07-04

5.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391
  5 in total
  16 in total

1.  Cytomegalovirus retinitis misdiagnosed as Hodgkin's lymphoma deposits.

Authors:  J L Toy; R P Knowlden
Journal:  Br Med J       Date:  1978-11-18

Review 2.  Current Treatment Options for Older Patients with Hodgkin Lymphoma.

Authors:  Jordan Carter; Kevin A David; Athena Kritharis; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

3.  Chemotherapy and irradiation in childhood Hodgkin's disease.

Authors:  B Robinson; J Kingston; R Nogueira Costa; J S Malpas; A Barrett; T J McElwain
Journal:  Arch Dis Child       Date:  1984-12       Impact factor: 3.791

4.  The pharmacokinetics of prednimustine and chlorambucil in the rat.

Authors:  D R Newell; C R Shepherd; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06

6.  Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.

Authors:  R E Taylor; T J McElwain; A Barrett; M J Peckham
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

Review 9.  Childhood lymphoma.

Authors:  K Windebank
Journal:  Indian J Pediatr       Date:  1998 Sep-Oct       Impact factor: 5.319

10.  British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.

Authors:  B W Hancock; G Vaughan Hudson; B Vaughan Hudson; J L Haybittle; M H Bennett; K A MacLennan; A M Jelliffe
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.